Canaccord Genuity Upgrades Staar Surgical to Buy, Raises Price Target to $27

Benzinga Newsdesk www.benzinga.com Positive 82.1%

Neg 0% Neu 0% Pos 82.1%

Canaccord Genuity analyst John Young upgrades Staar Surgical (NASDAQ:STAA) from Hold to Buy and raises the price target from $22 to $27.